CD34⁺selected cells in clinical transplantation

Abstract

The CD34 antigen is expressed by early hematopoietic stem cells and progenitors and is detected on the surface of approximately 1% of bone marrow mononuclear cells [1-3]. Several monoclonal antibody-based methods have been developed to isolate these cells from clinical samples of bone marrow or peripheral blood based on their expression of this antigen, utilizing either biotin-avidin affinity, panning or immunomagnetic beads. Roughly 50% of CD34+ cells, with 20-90% purity, are recovered from clinical samples using these methods. Several clinical trials have demonstrated hematopoietic recovery using CD34+ selected cells to support high dose therapy. CD34+ cells may be useful in several areas of clinical stem cell transplantation, including purging of tumor cells, T cell depletion, stem cell expansion and gene therapy. This paper reviews the current methods for purification of CD34+ cells from clinical samples and discusses potential uses of these cells in transplantation.

Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia

“…Both peripheral blood and bone marrow human CD34+ cells are enriched for HSC/P and capable of trilineage hematopoietic reconstitution upon transplantation [67,68]. Mobilization and collection of peripheral blood and bone marrow CD34+ cells in FA patients poses particular challenges related to the nature of this bone marrow failure disease [34,35,69].…”

The Removal of Human Breast Cancer Cells from Hematopoietic CD34+Stem Cells by Dielectrophoretic Field-Flow-Fractionation

“…A U TOLO GO US S TEM C ELL TR AN SPL AN TATION for reconstituting a cancer patient's hematopoietic system following dose-intensive chemotherapy and radiation therapy can be confounded by metastatic tumor cell contamination of the graft, which may cause disease recurrence (1)(2)(3)(4)(5). Currently, tumor cells are purged from autografts by pharmacologic, immunologic, or biophysical methods (6) or by positive selection of hematopoietic stem cells (HSC) with CD34 antibody-sensitized magnetic beads (7,8).…”

Low CD34 collection from a healthy blood progenitor cell donor: A case report

“…In this case, the cells mobilized appropriately, but collection was paradoxically impaired. As the CD34 molecule is involved in cell adhesion [5,6], one consideration is whether overly tight adhesion may have contributed to the poor separation and collection seen in this donor.…”